- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 452313, 7 pages
Antidiabetic Effects of Add-On Gynostemma pentaphyllum Extract Therapy with Sulfonylureas in Type 2 Diabetic Patients
1Endocrine and Diabetes Unit, Department of Molecular Medicine and Surgery, Karolinska Institute,17176 Stockholm, Sweden
2Hanoi Medical University, 1000 Hanoi, Vietnam
3National Institute of Gerontology, 1000 Hanoi, Vietnam
4Department of Material Medica, Hanoi College of Pharmacy, 1000 Hanoi, Vietnam
5Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2
Received 9 April 2012; Accepted 25 September 2012
Academic Editor: Benny Tan Kwong Huat
Copyright © 2012 V. T. T. Huyen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004.
- N. Winer and J. R. Sowers, “Epidemiology of diabetes,” Journal of Clinical Pharmacology, vol. 44, no. 4, pp. 397–405, 2004.
- R. R. Holman, “Long-term efficacy of sulfonylureas: a United Kingdom prospective diabetes study perspective,” Metabolism, vol. 55, no. 1, pp. S2–S5, 2006.
- R. C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49),” Journal of the American Medical Association, vol. 281, no. 21, pp. 2005–2012, 1999.
- A. Norberg, K. H. Nguyen, E. Liepinsh et al., “A novel insulin-releasing substance, phanoside, from the plant Gynostemma pentaphyllum,” Journal of Biological Chemistry, vol. 279, no. 40, pp. 41361–41367, 2004.
- N. K. Hoa, Å. Norberg, R. Sillard et al., “The possible mechanisms by which phanoside stimulates insulin secretion from rat islets,” Journal of Endocrinology, vol. 192, no. 2, pp. 389–394, 2007.
- S. Megalli, N. M. Davies, and B. D. Roufogalis, “Anti-hyperlipidemic and hypoglycemic effects of Gynostemma pentaphyllum in the Zucker fatty rat,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 3, pp. 281–291, 2006.
- T. M. Hung, D. M. Hoang, J. C. Kim, H. S. Jang, J. S. Ahn, and B. S. Min, “Protein tyrosine phosphatase 1B inhibitory by dammaranes from Vietnamese Giao-Co-Lam tea,” Journal of Ethnopharmacology, vol. 124, no. 2, pp. 240–245, 2009.
- V. T. T. Huyen, D. V. Phan, P. Thang, N. K. Hoa, and C. G. Östenson, “Antidiabetic effect of Gynostemma pentaphyllum tea in randomly assigned type 2 diabetic patients,” Hormone and Metabolic Research, vol. 42, no. 5, pp. 353–357, 2010.
- Department of Material Medica, Hanoi College of Pharmacy, Textbook of Material Medica, vol. 1, 2006.
- Department of Material Medica, Hanoi College of Pharmacy, Guideline of Material Medica Practice, vol. 1, 2006.
- WHO, “Definition, diagnosis, and classification of diabetes mellitus and its complications,” Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus, World Health Organization, Geneva, Switzerlands, 1999.
- V. Herbert, K. S. Lau, C. W. Gottlieb, and S. J. Bleicher, “Coated charcoal immunoassay of insulin,” Journal of Clinical Endocrinology and Metabolism, vol. 25, no. 10, pp. 1375–1384, 1965.
- D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.
- M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel, “One-year glycemic control with a suifonyurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 1, pp. 141–147, 2004.
- M. Roghani and T. Baluchnejadmojarad, “Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechin-gallate in streptozotocin-diabetic rats,” Pathophysiology, vol. 17, no. 1, pp. 55–59, 2010.
- R. Nahas and M. Moher, “Complementary and alternative medicine for the treatment of type 2 diabetes,” Canadian Family Physician, vol. 55, no. 6, pp. 591–596, 2009.
- H. Tsuneki, M. Ishizuka, M. Terasawa, J. B. Wu, T. Sasaoka, and I. Kimura, “Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans,” BMC Pharmacology, vol. 4, article no. 18, 2004.
- M. B. Davidson and A. L. Peters, “An overview of metformin in the treatment of type 2 diabetes mellitus,” American Journal of Medicine, vol. 102, no. 1, pp. 99–110, 1997.
- G. Charpentier, F. Fleury, M. Kabir, L. Vaur, and S. Halimi, “Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients,” Diabetic Medicine, vol. 18, no. 10, pp. 828–834, 2001.
- H. W. Rodbard, L. Blonde, S. S. Braithwaite et al., “American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus,” Endocrine Practice, vol. 13, supplement 1, pp. 1–68, 2007.
- J. Belsey and G. Krishnarajah, “Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis,” Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 1–7, 2008.